Knowledge-Driven New Drug Recommendation

• URL: http://arxiv.org/abs/2210.05572v1
• Date: Tue, 11 Oct 2022 16:07:52 GMT
• Title: Knowledge-Driven New Drug Recommendation
• Authors: Zhenbang Wu, Huaxiu Yao, Zhe Su, David M Liebovitz, Lucas M Glass, James Zou, Chelsea Finn, Jimeng Sun
• Abstract summary: We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
• Score: 88.35607943144261
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Drug recommendation assists doctors in prescribing personalized medications to patients based on their health conditions. Existing drug recommendation solutions adopt the supervised multi-label classification setup and only work with existing drugs with sufficient prescription data from many patients. However, newly approved drugs do not have much historical prescription data and cannot leverage existing drug recommendation methods. To address this, we formulate the new drug recommendation as a few-shot learning problem. Yet, directly applying existing few-shot learning algorithms faces two challenges: (1) complex relations among diseases and drugs and (2) numerous false-negative patients who were eligible but did not yet use the new drugs. To tackle these challenges, we propose EDGE, which can quickly adapt to the recommendation for a new drug with limited prescription data from a few support patients. EDGE maintains a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. Specifically, EDGE leverages the drug ontology to link new drugs to existing drugs with similar treatment effects and learns ontology-based drug representations. Such drug representations are used to customize the metric space of the phenotype-driven patient representations, which are composed of a set of phenotypes capturing complex patient health status. Lastly, EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. We evaluate EDGE on two real-world datasets: the public EHR data (MIMIC-IV) and private industrial claims data. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.

Related papers

• Leave No Patient Behind: Enhancing Medication Recommendation for Rare Disease Patients [47.68396964741116]
  We propose a novel model called Robust and Accurate REcommendations for Medication (RAREMed) to enhance accuracy for rare diseases. It employs a transformer encoder with a unified input sequence approach to capture complex relationships among disease and procedure codes. It provides accurate drug sets for both rare and common disease patients, thereby mitigating unfairness in medication recommendation systems.
  arXiv  Detail & Related papers  (2024-03-26T14:36:22Z)
• Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening [38.94493676651818]
  We propose a zero-shot learning solution for the. task in preclinical drug screening. Specifically, we propose a Multi-branch Multi-Source Domain Adaptation Test Enhancement Plug-in, called MSDA.
  arXiv  Detail & Related papers  (2023-10-05T05:55:41Z)
• NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug Candidates Through an Integrated Computational Approach [0.0]
  Drug repurposing is an emerging approach for drug discovery involving the reassignment of existing drugs for novel purposes. A proposed algorithm is NeuroCADR, a novel system for drug repurposing via a multi-pronged approach consisting of k-nearest neighbor algorithms (KNN), random forest classification, and decision trees. Data was sourced from several databases consisting of interactions between diseases, symptoms, genes, and affiliated drug molecules, which were then compiled into datasets expressed in binary. NeuroCADR identified novel drug candidates for epilepsy that can be further approved through clinical trials.
  arXiv  Detail & Related papers  (2023-09-04T03:21:43Z)
• ADRNet: A Generalized Collaborative Filtering Framework Combining Clinical and Non-Clinical Data for Adverse Drug Reaction Prediction [49.56476929112382]
  Adverse drug reaction (ADR) prediction plays a crucial role in both health care and drug discovery. We propose ADRNet, a generalized collaborative filtering framework combining clinical and non-clinical data for drug-ADR prediction.
  arXiv  Detail & Related papers  (2023-08-03T11:28:12Z)
• Conditional Generation Net for Medication Recommendation [73.09366442098339]
  Medication recommendation targets to provide a proper set of medicines according to patients' diagnoses, which is a critical task in clinics. We propose Conditional Generation Net (COGNet) which introduces a novel copy-or-predict mechanism to generate the set of medicines. We validate the proposed model on the public MIMIC data set, and the experimental results show that the proposed model can outperform state-of-the-art approaches.
  arXiv  Detail & Related papers  (2022-02-14T10:16:41Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• Drug Package Recommendation via Interaction-aware Graph Induction [44.493214829186115]
  We propose a new Drug Package Recommendation (DPR) framework with two variants, respectively DPR on Weighted Graph (DPR-WG) and DPR on Attributed Graph (DPR-AG) In detail, a mask layer is utilized to capture the impact of patient condition, and graph neural networks (GNNs) are leveraged for the final graph induction task to embed the package.
  arXiv  Detail & Related papers  (2021-02-06T12:51:00Z)
• When deep learning meets causal inference: a computational framework for drug repurposing from real-world data [12.68717103979673]
  Existing methods for drug repurposing may exist translational issues when applied to human beings. We present an efficient and easily-customized framework for generating and testing multiple candidates for drug repurposing. We demonstrate our framework in a case study of coronary artery disease (CAD) by evaluating the effect of 55 repurposing drug candidates on various disease outcomes.
  arXiv  Detail & Related papers  (2020-07-16T21:30:56Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.